Varenicline
| Varenicline | |
|---|---|
| Salts [] | |
|---|---|
| Varenicline salicylate | |
| Varenicline oxalate | |
| Varenicline tartrate | |
| Varenicline citrate | |
| Varenicline besylate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 211.26 g/mol [1] |
| Decomposition | Hazardous decomposition products: Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx) [1] |
| Solubility | 8.77e-02 g/L [1] |
| Predicted LogP | 0.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C13H13N3 |
| IUPAC name | (1S,12R)-5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene |
| SMILES | C1[C@@H]2CNC[C@H]1C3=CC4=NC=CN=C4C=C23 |
| InChI | InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+ |
| InChIKey | JQSHBVHOMNKWFT-DTORHVGOSA-N |
| CAS number | 249296-44-4 |
| UNII | W6HS99O8ZO |
| PubChem CID | 5310966 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 24 hours |
| Metabolism | Primarily unchanged by OCT2. Insignificant CYP450 enzyme involved |
| Excretion | Kidney (81–92%) |
| Routes of administration | By mouth, intranasal |
Varenicline (also known as vareniclina, vareniclinum, Cp 526555, Cp-526,555, Cp-526555, 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine, 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine, (1R,12S)-5,8,14-triazatetracyclo(10.3.1.02,11.04,9)hexadeca-2,4,6,8,10-pentaene, 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine or N07ba03) is a substance of the phenethylamine class.
Chemistry
Salts []
Stereochemistry []
Varenicline is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Varenicline matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- other nervous system drugs (N07)
- drugs used in addictive disorders (N07B)
- drugs used in nicotine dependence (N07BA)
- (N07BA03)
- varenicline (N07BA03)
- sensory organs (S)
- ophthalmologicals (S01)
- other ophthalmologicals (S01X)
- other ophthalmologicals (S01XA)
- varenicline (S01XA28)
MeSH Classification
- smoking cessation agents (M000640785)
- nicotinic agonists (M0028051)
Mechanism of action []
Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectivity for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms. [1]
Medical side effects []
280 side effects listed on drug labels in SIDER 4.1 (varenicline).
- Nausea
- Insomnia
- Headache
- Abnormal dreams
- Flatulence
- Constipation
- Dysgeusia
- Asthenia
- Fatigue
- Abdominal pain
- Gastrointestinal pain
- Arthralgia
- Musculoskeletal discomfort
- Myalgia
- Back pain
- Chest pain
- Chest discomfort
- Depression
- Diarrhoea
- Dizziness
- Syncope
- Dyspepsia
- Oedema
- Epistaxis
- Gingivitis
- Hyperhidrosis
- Hypertension
- Irritability
- Menstrual disorder
- Muscle spasms
- Musculoskeletal pain
- Polyuria
- Urine output increased
- Thirst
- Weight increased
- Dry mouth
- Liver function test abnormal
- Sensory disturbance
- Disturbance in attention
- Emotional disorder
- Rash generalised
- Influenza like illness
- Menopausal symptoms
- Hot flush
- Malaise
- Discomfort
- Feeling abnormal
- Ill-defined disorder
- Increased appetite
- Sleep disorder
- Sleep disturbance
- Vomiting
- Somnolence
- Dermatitis
- Rash
- Nightmare
- Decreased appetite
- Dyspnoea
- Gastrooesophageal reflux disease
- Lethargy
- Amnesia
- Anaemia
- Angina pectoris
- Arrhythmia
- Arthritis
- Asthma
- Bronchitis
- Musculoskeletal chest pain
- Tongue coated
- Conjunctivitis
- Cough
- Cyst
- Libido decreased
- Disturbance in sexual arousal
- Libido increased
- Dysphagia
- Diabetes mellitus
- Eczema
- Enterocolitis
- Eructation
- Oesophagitis
- Body temperature increased
- Gallbladder disorder
- Gastritis
- Gastrointestinal haemorrhage
- Glycosuria
- Haematemesis
- Haematochezia
- Dysphonia
- Hyperlipidaemia
- Hypoaesthesia
- Hypokalaemia
- Hypotension
- Menorrhagia
- Hypertonia
- Fungal infection
- Mydriasis
- Myocardial infarction
- Acute coronary syndrome
- Myopia
- Nasopharyngitis
- Rhinorrhoea
- Night sweats
- Nocturia
- Osteoporosis
- Palpitations
- Upper-airway cough syndrome
- Pruritus
- Psoriasis
- Restless legs syndrome
- Salivary hypersecretion
- Sinusitis
- Snoring
- Aphthous stomatitis
- Shock
- Loss of consciousness
- Tachycardia
- Thrombosis
- Thyroid disorder
- Costochondritis
- Tinnitus
- Tremor
- Erythema
- Urticaria
- Varicose vein
- Vertigo
- Viral infection
- Chills
- Polydipsia
- Agitation
- Mood swings
- Affect lability
- Dissociation
- Stomatitis
- Mouth ulceration
- Migraine
- Ventricular extrasystoles
- Eye pain
- Dry skin
- Hypogeusia
- Sinus congestion
- Lacrimation increased
- Urethral syndrome
- Abnormal faeces
- Joint stiffness
- Vaginal discharge
- Disorientation
- Dysphoria
- Thinking abnormal
- Mental disability
- Eye irritation
- Peripheral ischaemia
- Urine abnormality
- Urine analysis abnormal
- Semen analysis abnormal
- Scleral discolouration
- Gingival pain
- Erectile dysfunction
- Change of bowel habit
- Dry eye
- Vision blurred
- Platelet count decreased
- Nephrolithiasis
- Bradycardia
- Electrocardiogram T wave amplitude decreased
- Lymphadenopathy
- Blood pressure increased
- Electrocardiogram ST segment depression
- Coordination abnormal
- Electrocardiogram abnormal
- Visual impairment
- Throat irritation
- Acne
- C-reactive protein increased
- Laryngeal pain
- Circadian rhythm sleep disorder
- Respiratory tract congestion
- Muscle enzyme increased
- Parosmia
- Blood calcium decreased
- Pancreatitis acute
- Aggression
- Angioedema
- Anxiety
- Atrial fibrillation
- Mental disorder
- Transient ischaemic attack
- Deafness
- Delusion
- Drug hypersensitivity
- Dysarthria
- Osteoarthritis
- Erythema multiforme
- Stevens-Johnson syndrome
- VIIth nerve paralysis
- Vitreous floaters
- Cardiac flutter
- Hallucination
- Hostility
- Hyperglycaemia
- Hyperkalaemia
- Hypersensitivity
- Hypoglycaemia
- Intestinal obstruction
- Renal failure acute
- Leukocytosis
- Meniere's disease
- Multiple sclerosis
- Myositis
- Nystagmus
- Panic reaction
- Pleurisy
- Psychotic disorder
- Paranoia
- Pulmonary embolism
- Cor pulmonale
- Scotoma
- Convulsion
- Splenomegaly
- Gastric ulcer
- Cerebrovascular accident
- Completed suicide
- Suicide attempt
- Thrombocytopenia
- Urinary retention
- Photophobia
- Drug withdrawal syndrome
- Night blindness
- Blindness transient
- Photosensitivity reaction
- Euphoric mood
- Cataract subcapsular
- Mania
- Depressed mood
- Suicidal ideation
- Homicidal ideation
- Sexual dysfunction
- Bradyphrenia
- Balance disorder
- Psychomotor skills impaired
- Ocular vascular disorder
- Mental retardation
- Coronary artery disease
- Abdominal distension
- Anger
- Breast disorder
- Infection
- Connective tissue disorder
- Endocrine disorder
- Eye disorder
- Frustration
- Gastrointestinal disorder
- Cardiac disorder
- Immune system disorder
- Mediastinal disorder
- Nervous system disorder
- Pain
- Somnambulism
- Toothache
- Pollakiuria
- Urethral disorder
- Urinary tract disorder
- Angiopathy
- Peripheral vascular disorder
- Oedema peripheral
- Injury
- Malnutrition
- Skin disorder
- Abdominal pain upper
- Abnormal behaviour
- Extrapyramidal disorder
- Tenderness
- Abdominal discomfort
- Hepatobiliary disease
- Initial insomnia
- Middle insomnia
- Terminal insomnia
- Infestation
- Upper respiratory tract inflammation
- Rhinitis allergic
Indications
- Cardiovascular disorder
- Chronic obstructive pulmonary disease
- Function kidney decreased
- Schizoaffective disorder
- Schizophrenia
- Suicidal behaviour
Experience reports
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5310966, Varenicline. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5310966
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Varenicline. UNII: W6HS99O8ZO. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/W6HS99O8ZO
Champix Product Information. Therapeutic Goods Administration (TGA). 26 September 2021. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06102-3
Champix varenicline (as tartrate) 0.5 mg and 1.0 mg tablet blister pack. Therapeutic Goods Administration (TGA). https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=124940
Product information. Health Canada. 22 October 2009. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77655
Champix 0.5 mg film-coated tablets - Summary of Product Characteristics (SmPC). (emc). https://www.medicines.org.uk/emc/product/266/smpc
Tyrvaya- varenicline spray. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=014c93dc-5737-479c-a9f0-aaadac1ac298
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 12:00:05 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 12:00:01 |
| erowid | ok | 2026-11-20 12:00:03 |
| gsrs | ok | 2026-11-20 12:00:05 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015398) | 2026-11-20 12:00:01 |
| kegg | ok | 2026-11-20 12:00:03 |
| pubchem | ok | 2026-11-20 12:00:01 |
| missing (no r/tripreports posts mention it) | 2026-11-20 12:00:01 | |
| sider | ok | 2026-11-20 12:00:02 |
| structure | ok | 2026-11-20 12:00:01 |
| wikipedia | ok | 2026-11-20 12:00:02 |